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1. Introduction 
Colorectal carcinoma (CRC) is one of the most frequent cancers in western societies, with an 
incidence of approximately 700 per million people. Every year there are approximately 
125,000 new cases of colon cancer in the U.S. Fifteen percent of these patients will have liver 
metastases at the time of diagnosis, and another 50% will develop liver metastatic disease 
during the course of their disease (Kemeny et al., 2004).  Although median survival of 
patients with untreated metastatic CRC is around 6 months, recent advances in adjuvant 
therapy after the colon resection offer the promise of a decrease in the number of cases with 
metastatic disease (Andre et al., 2004).  Just as important, for the patients with liver 
metastatic disease, newer chemotherapeutic agents such as irinotecan and oxaliplatin, as 
well as new targeted agents such as cetuximab and bevacizumab in the current protocols 
have improved response rates and survival (Cunningham et al., 2004; Douillard et al., 2000; 
De Gramont et al., 2000; Hurwitz et al., 2004; Tournigand et al., 2004).  Unfortunately, even 
with these combinations, the two-year survival is limited to 40% at best for patients with 
metastatic disease and only about 10% of patients with metastatic CRC survive beyond 5 
years (McCarter & Fong, 2000). 
These findings make surgical treatment the cornerstone of the therapeutic approach to this 
disease.  Although only 10-25% of patients with liver metastatic disease are candidates for 
surgical resection, a combined therapeutic approach has shown the most promise, especially 
since it has been possible to convert around 15%-30% of previously considered unresectable 
patients and achieve survivals similar to the ones deemed resectable from the beginning 
(Bismuth et al., 1996).  The majority of patients who undergo liver resection for metastases 
will experience intra- and/or extra-hepatic relapse of the disease.  Even so, it has been 
demonstrated that resection of liver metastases increases survival, with 5-year survival rates 
of 30-50% in patients undergoing curative resections for their metastatic disease compared 
to 5-10% for non-operated patients (Fong et al., 1997; Kemeny et al., 2004; Scheele et al., 
1990). 
2. Defining resectable disease 
The first question that has to be answered is what is considered resectable disease, a concept 
that has evolved significantly over time. Originally, it was felt that more than three 
metastatic liver lesions or patients with bilobar disease were not appropriate for resection.  
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However, more recent studies have shown that even in patients with poor prognostic signs, 
5-year survival can be achieved after curative liver resection (Poston et al., 2005; Fong et al., 
1999; Nordlinger et al., 1996).  Despite the potential for cure, formal staging for liver 
metastases has not changed and remains stage IV along with incurable metastatic disease. 
The effort has thus been to identify appropriate selection criteria that allow discrimination 
of patients that would or would not benefit from surgical intervention. The value of these 
prognostic scoring systems is based on a combination of ability to predict outcome, as well 
as simplicity. Different studies have used a variety of prognostic features including age, 
number of metastases, size of the largest lesion, carcino-embryonic antigen (CEA) level, 
primary tumor stage, positive tumor resection margins, disease-free interval, positive lymph 
nodes from the primary, and have attempted to provide risk scores based on these factors 
(Fong et al., 1999; Nordlinger et al., 1996; Poston et al., 2005).  Normograms have also been 
proposed as a potential improvement upon previous scoring systems. Rather than count risk 
factors, a normogram takes the specific value for each factor into account and calculates a 
specific score for each patient (Kattan et al., 2008).  This leads to a potentially more accurate 
prediction, as it is specific to each patient. There is common agreement, however, in all these 
studies that although poor characteristics and high risk scores will definitely decrease 
survival, 5-year survival was still better compared to those patients with liver metastatic 
disease that had not undergone resection. As a result, none of these series suggested that 
patients with poor prognostic signs should not undergo surgery.   
The indications have changed over time to the extent that currently a surgical resection 
would be of benefit if it is possible after resection to get an R0 resection, leave behind at least 
two contiguous segments and functional liver volume >20%. As it will be discussed later, 
even extra-hepatic metastatic disease is not necessarily a contraindication and more patients 
are being considered for resection (Khatri et al., 2005). Advances that have played a central 
role in this include preoperative portal vein embolization to induce hypertrophy of the 
nondiseased part of the liver that would remain behind, better vascular clamping 
techniques, controlled anatomic resection, the use of radiofrequency and microwave 
ablation for small lesions that may remain in the liver left behind after a resection, and more 
recently the use of image-guided liver surgery (Cash et al., 2007; Couinaud 1957; Curley et 
al., 1999; Fong & Wong 2009; Makuuchi et al., 1987, 1990). 
Portal vein embolization (Figure 1) has allowed surgeons to be more aggressive in the 
treatment of CRC hepatic metastases, as one of the contraindications was a small future liver 
remnant (FLR) in patients with a small left lateral lobe who require an extended right 
hepatectomy. The small residual liver volume increases the risk of postoperative hepatic 
failure, and so in patients without cirrhosis a FLR of non-tumor volume of 25-30% is 
considered safe for hepatic resection. Selective portal vein embolization can produce 
atrophy of the segments affected by the cancer and compensatory hypertrophy of the 
contralateral segments, providing an increase of 10-30% in the FLR. Overall, there is no 
agreement that any specific substance is significantly better for the embolization. As helpful 
as this technique is, there have been several concerns raised. One potential difficulty for 
patients with metastatic CRC is that portal vein embolization may end up promoting tumor 
growth, thereby increasing the incidence of recurrence following liver resection. However, 
in a study of the long term survival following portal vein embolization, with 41 patients 
with CRC liver metastases, there was no evidence to suggest that patients whose surgery 
had been made possible by this technique were associated with a poorer long term survival 
(Elias et al., 2002). Given that the waiting time between embolization and resection is 
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usually around 6 weeks, an additional concern is the effect of chemotherapy administered 
during the periprocedural period on the FLR hypertrophy and on the tumor growth in 
embolized segments in patients with CRC liver metastases. In a study of patients receiving 
chemotherapy after the portal vein embolization, FLR hypertrophied whether the patient 
had received chemotherapy or not; however, the hypertrophy was significantly less in those 
patients that had received post-embolization chemotherapy suggesting that although 
chemotherapy is not contraindicated, it should be considered carefully in those patients 
requiring a large compensatory hypertrophy (Beal et al., 2006). 
 
 
Fig. 1. Embolization of right portal vein branch to induce hypertrophy of the future left lobe 
remnant in anticipation of planned hepatectomy. 
3. The role of chemotherapy 
The targeted use of chemotherapy, such as 5-fluorouracil, Leucovorin and Oxaliplatin 
(FOLFOX) and 5-fluorouracil, Leucovorin and Irinotecan (FOLFIRI) has been critical in 
increasing resectability with rates ranging from 10% to 35% (Alberts et al., 2005; Ho et al., 
2005; Masi et al., 2006; Wein et al., 2003).  Comparisons have been somewhat difficult 
because of the different ways that unresectability is perceived or defined. Some studies 
include number of lesions or bilobar disease, whereas others look at more technical issues, 
such as involvement of all three hepatic veins, both portal veins, or the retrohepatic vena 
cava, or that resection would leave less than two segments or not an adequate liver reserve. 
Even with these limitations, there is definitely a role for neoadjuvant treatment in moving 
from unresectable disease to surgical cure (Figure 2 a, b, c). 
More interesting is the question of the use of chemotherapy prior to resection in the case of 
resectable lesions. Arguments in favor include the decrease in tumor size, the potential 
control of micrometastatic disease, the assessment of the activity of chemotherapy as a 
method of in vivo chemosensitivity, improved chemotherapy tolerance, and a potential 
marker for the success of liver surgery (Adam et al., 2004; Fong et al., 1999; Nordlinger et al., 
1996; Poston et al., 2005; Sauer et al., 2004). Arguments against preoperative chemotherapy 
use in resectable patients include liver toxicity (chemotherapy-associated steatohepatitis or 
CASH), risk of progression or growth in other sites, selection of resistant clones and the fact 
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Fig. 2. a, b, c: Example of a good response to chemotherapy leading to resection of the 
metastatic disease. (a) CT of a patient with a large left lobe liver metastatic lesion from CRC. 
(b) Decrease in size of metastatic lesion after a full course of chemotherapy. (c) CT scan after 
the patient underwent a left hepatectomy and a radiofrequency ablation of a lesion on the 
right. 
that response may make the surgery more difficult (Fernandez et al., 2005; Karakousis & 
Fong, 2009; Kooby et al., 2003). Specifically, as 70% of patients respond to cetuximab and 
FOLFOX chemotherapy and another 25% have stable disease, it is a very small percentage of 
5-10% who may experience disease progression while receiving first line chemotherapy 
(Nordlinger et al., 2008; Tabernero et al., 2007). As a result, it is only after failure of first line 
chemotherapy that the concept of in vivo chemosensitivity makes sense. More importantly, 
advances in identifying molecular patterns and predictors of response have increased the 
value of resection, as such a strategy would make it possible to interrogate the tissues 
completely and potentially choose the best chemotherapy. One such example is the finding 
that tumor analysis for K-ras mutation status can be used as a predictor of response to 
cetuximab and oxaliplatin (Bibeau et al., 2009). Another problem with neoadjuvant 
chemotherapy for resectable lesions is that in a recent study only 66% of disappearing liver 
metastases following chemotherapy were complete responses, which means that a 
significant percentage of metastatic lesions were still present as the result of a reduction in 
the sensitivity of imaging during chemotherapy (Auer et al., 2010). This could lead to 
incomplete, noncurative resections. Overall, the prevailing opinion appears to be that, 
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unless the lesions are metachronous and of borderline resectability, they should be resected 
first with chemotherapy to follow (Figure 3). 
 
 
Fig. 3. Proposed algorithm for the treatment of liver metastases from CRC regarding the role 
of surgery and chemotherapy. 
Regarding the question of adjuvant treatment of choice, there is agreement that adjuvant 
therapy after liver resection is useful. If a patient has not received any prior chemotherapy, 
treatment with 5-fluorouracil/leucovorin or FOLFOX are both reasonable choices, although 
there is definitely a need for further trials in the adjuvant setting (Park et al., 2007; Portier et 
al., 2006). For patients that fail first line adjuvant therapy molecular profiles, when available, 
may help in determining the optimal treatment. If a patient’s disease has failed to respond to 
FOLFOX or FOLFIRI, then there exist options such as irinotecan/cetuximab or 
Xeloda/bevacizumab, treatments with a high cost of about $100,000 for 6 months. These 
patients need to be enrolled in registries and treated under protocols, so that decisions can 
be made based on available data. 
4. Pre- and intra-operative plan 
4.1 Pre-operative planning 
It was not unusual having percentages as high as 40% of patients found to be unresectable 
during surgery, mainly because of the difficulties in properly assessing the location and 
number of metastatic lesions (Steele et al., 1991). Progress has been made and in order to 
determine the resectability of the lesion preoperatively, radiologic studies can offer valuable 
information. Specifically, a triple phase CT with volumetry can be used to identify the 
location and vascular supply of the lesions and serve as a road map, as well as an estimate 
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of whether a resection would leave behind an adequate liver remnant. More advanced 
versions of this are the computer-generated models that allow an image-guided approach to 
the resection of these lesions, even in real time (Cash et al., 2007; Fong & Wong, 2009). One 
example is the MeVis software package from HepaVision (Bremen, Germany) which allows 
a computer-assisted 3D surgery planning. This leads to improved pre-operative planning on 
how to gain better access to the metastatic lesions even in regions at risk for 
devascularization or impaired drainage.  Also, the volume of the remaining liver 
parenchyma is calculated separately for each resection proposal (Figure 4). 
 
 
Fig. 4. 3D modelling of a large right lobe metastatic lesion based on CT data obtained using 
the MeVis system (HepaVision, Bremen, Germany), that allows visualization of the 
vasculature of the mass, as well as its relation to the venous drainage system of the liver and 
an estimation of the remaining liver volume based on the proposed resection plane. 
It is also important to perform a thorough search for extrahepatic disease, to either exclude 
the patient from resection, or at least have a plan that would address the different sites of 
metastatic disease.  For a patient with isolated liver metastatic disease, a CT of the chest, 
abdomen and pelvis is performed at first to identify the full extent of the hepatic disease, as 
well as discover any extrahepatic disease.  FDG-PET has also been used to both identify the 
presence of hepatic colorectal metastases and to improve the staging of patients under 
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consideration for resection (Truant et al., 2005). Although PET can be a valuable resource in 
helping define whether a lesion is metastatic or not, there are limitations, such as the fact 
that it may miss small lesions, it is expensive, and that it may be affected by recent 
administration of chemotherapy. Hepatic lesions identified should not be biopsied as there 
is a real risk of extrahepatic dissemination of tumor with percutaneous biopsies (Metcalfe et 
al., 2004). 
4.2 Intra-operative planning 
This diligence should continue intraoperatively, where laparoscopy at the beginning of the 
surgery may identify occult metastatic disease that may prevent an unnecessary 
laparotomy. Furthermore, the use of intraoperative ultrasound is almost mandatory, both to 
identify the known lesions and their location in relation to the surrounding vessels, as well 
as to look for other lesions that may not have been detected preoperatively (Figure 5). 
Intraoperative ultrasound allows confirmation of expected sites of disease and may detect 
additional lesions in 10-50% of cases (Machi et al., 1991; Makuuchi et al., 1991).  
Confirmation of the hepatic vascular anatomy in relation to the lesion and identification of 
specific segmental pedicles give the surgeon the opportunity to obtain a clear demarcation 
line in the parenchyma by occluding the vascular pedicle responsible. This allows resection 
of only the involved parenchyma with an exact transection plane. 
 
 
Fig. 5. Intraoperative US of the liver during a laparoscopic liver resection. 
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Regarding the technical part of the resection, the aim is to resect the liver parenchyma with 
minimal bleeding, avoiding biliary leaks and leaving adequate functional liver. Various 
techniques can be used according to surgeon preference to achieve this, including the use of 
hemostatic clamps, the handle of a scalpel, or finger fracture. More recently, there is 
widespread use of ultrasonic dissection using ultrasonic aspirators (an acoustic vibrator, 
perfused with saline, which disrupts the liver parenchyma by producing a cavitational 
force), or other instruments such as water-jet dissection or ultrasonic cutting.  Prior to 
division of the parenchyma, whenever possible, vascular occlusion can be attempted to 
minimize bleeding, and which is subsequently released at the end of the parenchymal 
dissection. 
Over the last several years there has been a more aggressive approach undertaken by many 
surgeons in the treatment of CRC liver metastases, based on the significant improvements in 
surgical techniques, adjunctive treatments such as portal vein embolization and 
radiofrequency ablation, and the effectiveness of newer chemotherapeutic regimens. This 
has led to a change in surgical approach with an increase of nonanatomical resections (Gold 
et al., 2008). This technique maximizes the amount of residual parenchyma, which is 
important for patients at risk for hepatic insufficiency, as well as in those that have received 
chemotherapy (Figure 6 a,b). 
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Fig. 6. a, b: (a) CT of a large CRC hepatic metastatic lesion. (b) Nonanatomical resection of 
central CRC hepatic metastatic lesion. 
Additionally, in case of intrahepatic recurrences after partial liver resection in patients with 
liver metastatic disease, a sufficient liver remnant allows the possibility of further surgical or 
ablative treatments (Figure 7 a,b). Sparing liver parenchyma may also mean minimizing the 
surgical stress involved for the patients as the surgery becomes more targeted, something 
which can translate to shorter operating times and decreased blood loss (Stewart et al., 
2004). 
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Fig. 7. a, b: (a) CT of a CRC hepatic metastatic lesion in a patient that had undergone a 
previous left hepatectomy for another metastatic lesion. (b) Nonanatomical repeat resection 
of metastatic lesion in close proximity to the hepatic veins. 
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5. Technical considerations & controversies 
5.1 Laparoscopic resection 
Since the first laparoscopic liver resection was reported in 1992, the number has increased 
significantly, numbering in the several thousands, as the technique offers the advantages 
over open surgery of reduced postoperative pain, less operative morbidity, shorter hospital 
stay, and faster recovery (Buell et al., 2008; Koffron et al., 2007). These lesions can be 
resected using a totally laparoscopic technique, a robotic-assisted minimally invasive 
technique, or a hand-assisted laparoscopic approach. The latter is considered as a safe first 
step in the learning curve, as it offers the surgeon the safety of having a hand inside the 
abdomen, thus making it easier to obtain vascular control, should that become necessary 
(Figure 8).  
 
 
Fig. 8. Port placement for the performance of a hand-assisted laparoscopic liver resection. 
Despite the early introduction of laparoscopic liver resection, the technique has not gained 
widespread acceptance. Most hepatobiliary centers perform only open liver surgery, and 
even in centers performing laparoscopic liver resections, the open procedures are still the 
majority. One reason is the technical challenge of the procedure, as it is time-consuming and 
difficult to master laparoscopic liver resection.  Especially for senior surgeons skilled in 
traditional hepatobiliary techniques, achieving mastery with a skill as complicated as 
laparoscopic liver resection may seem as a challenge not worth the effort. This can restrain 
the rapid development of laparoscopic hepatic resections in hepatobiliary centers. Another 
reason for the limited use of this technique is the fear that it represents a less oncologically 
sound method, by being less radical than the open procedure. This has not been shown to be 
the case, as laparoscopic liver resection does not appear to compromise oncological 
measures, such as margin status, disease-free survival and overall survival (Nguyen et al., 
2011). In a multicenter, international series of laparoscopic resection for colorectal carcinoma 
metastases in 109 patients there were no perioperative deaths and a complication rate of 
12% (Nguyen et al., 2009). The series included a significant number of major resections (45% 
were more than 3 segments) and negative margins were achieved in 94% of patients, with 
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overall survivals at 1-, 3- and 5-years of 88%, 69% and 50% respectively. These numbers are 
highly comparable to the open procedure regarding outcome.  
Although the outcome between open and laparoscopic liver resection may be similar, there 
are areas where the laparoscopic procedure appears to have the upper hand, including 
median hospital stay and morbidity (Buell et al., 2008; Koffron et al., 2007). Another 
increasingly relevant question is that of the cost. It has been found that patients undergoing 
laparoscopic surgery have higher operating room costs compared to patients undergoing an 
open liver resection; however, the total hospital costs are not different between the two 
groups, mainly because the laparoscopic group of patients are able to leave the hospital 
sooner (Nguyen et al., 2011). 
5.2 Treatment of synchronous metastases 
Synchronous liver metastases, commonly defined as liver metastases occurring within 12 
months of the colon primary, offer the challenge of the optimal timing for surgical resection. 
The original paradigm of the staged resection (colon primary first with the liver metastatic 
resection 2 to 3 months later), has begun to change and has evolved to one where good 
results can be achieved with simultaneous resection (Martin et al., 2003; Lyass et al., 2001). A 
study of 230 patients (70 undergoing simultaneous resection and 130 staged) revealed no 
difference in morbidity and mortality, but a significantly shorter hospital stay for the group 
undergoing simultaneous resection (Martin et al., 2009). The main limitation of this strategy 
is that it can only be offered to a limited number of patients with synchronous disease and 
that it is associated with an increased risk of postoperative complications as the patient 
undergoes two major surgeries in the same setting (Reddy et al., 2007). Recently, a “reverse 
strategy” has been advocated, in which preoperative chemotherapy is followed by resection 
of the CRC liver metastases first, followed by resection of the colorectal primary at a second 
stage (Mentha et al., 2006). This has been proposed for patients with advanced CRC liver 
metastases and a stable primary cancer, especially if it is a rectal one. The rationale is that 
complications (bleeding, perforation, obstruction) from the primary are rare in patients with 
stage IV CRC being treated with chemotherapy, and also that this way treatment of the 
metastatic disease is not delayed till completion of the treatment of the primary. A recent 
study has shown that all 3 strategies, namely the classic, the combined and the reverse in 
patients with synchronous presentation of liver metastases have similar outcomes (Brouquet 
et al., 2010). For this reason it is important to individualize the strategy according to the 
extent of the disease of both the primary and the metastases for each patient. 
5.3 Management of extrahepatic disease 
What was previously not an option, has gained significant ground as an aggressive 
multidisciplinary approach leads to long term survival in cases of serial metastasectomy of 
hepatic and pulmonary metastases from colon cancer. Studies have reported 5-year 
survivals of 51%, with the key being an aggressive approach where every time a metastatic 
lesion is identified, it is resected (Mineo et al., 2003; Nagakura et al., 2001; Shah et al., 2006). 
Although there have been reports of resection of portal lymph-nodes and peritoneal 
metastatic lesions, in addition to the hepatic ones, these should be viewed very cautiously as 
the results are rather disappointing (Adam et al., 2008; Yan et al., 2006). However, the 
possibility does remain that in time as our experience grows it may be possible to better 
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define long-term outcomes and identify biological markers that will predict tumor behavior, 
and thus enable a more aggressive approach. 
5.4 Is there a role for liver transplantation?  
The past experiences of liver transplantation for colorectal cancer liver metastases have led 
to long-term survival and even cure in some cases (Hoti &Adam, 2008; Kappel et al., 2006). 
This is not surprising since liver transplantation for liver-only metastatic disease is by 
definition an R0 resection and as such from an oncological perspective acceptable. However, 
from the perspective of liver transplantation, given the organ shortage, the outcome has to 
be comparable to other indications for liver transplantation. If we add to this the fact that 
overall survival following liver transplantation has dramatically improved and that patients 
with hepatic metastatic disease of colorectal origin present less of a technical challenge, 
given the lack of cirrhosis and portal hypertension, these patients should be considered 
relatively low-risk for liver transplantation. An additional argument is the use of a class of 
immunosuppressive medications, the mTOR inhibitors that have shown clinical effect and 
stabilization of disease for a variety of cancers, in their role as antiproliferative agents 
(Atkins et al., 2004; Chan et al., 2005; Fung et al., 2005). 
Based on these premises, a group from Norway, taking advantage of the surplus of donor 
organs in that country, initiated a study where 16 patients underwent liver transplantation 
for isolated hepatic metastatic colorectal disease (Foss et al., 2010). Although 2-year survival 
was 94%, there was a high recurrence rate of 63%, with an excellent quality of life. These 
preliminary data seem promising; however, it is too early to tell whether this is a beneficial 
strategy. Specifically, it is important to evaluate the 5-year survival in order to see whether it 
is comparable to other indications for liver transplantation so as to justify the use of a 
limited organ supply. In addition, selection criteria for the candidates need to be refined to 
be able to decrease the high recurrence rate. 
5.5 The role of combination therapy  
The same aggressive approach to the treatment of colorectal liver metastases, has led to the 
use of several treatment modalities in combination, which in turn has led to renewed efforts 
towards dealing with more advanced lesions. In a series of 224 patients, where a very high 
number had multiple (five or more) bilateral liver lesions, treatment consisted of a 
combination of hepatic arterial chemotherapy, cryotherapy and resection (Yan et al., 2006). 
This led to 1-, 3-, and 5-year survival rates of 87%, 43% and 23% respectively in this high risk 
group of patients. The surgeon and the medical team have a wide armamentarium in their 
hands and it is up to them to find the right treatment modality for the right patient. 
5.6 The role of ablative therapy  
A special mention should be made regarding the role of ablative therapy in the treatment of 
liver metastatic disease from colorectal cancer, and especially that of radiofrequency 
ablation (RFA). With this technique a probe is inserted into the lesion and through the 
transfer of current the lesion is heated to the level of 90 to 100 degrees centigrade (Figure 9). 
The use of this method has grown exponentially with the combined use of intraoperative 
ultrasound as smaller lesions can be localized more accurately.  Additionally, advances such 
as the use of multiple tines on these probes have made possible the ablation of bigger lesions 
up to 5 or 6cm. 
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Fig. 9. Radiofrequency ablation of hepatic metastatic lesion from colorectal cancer. 
As experience with RFA has increased over the last several years, there has been an effort to 
comprehensively evaluate the results. The American Society of Clinical Oncology in 2009 in 
a Clinical Evidence Review regarding RFA of hepatic metastases from colorectal cancer, 
suggests that, based on the existing evidence, hepatic resection improves overall survival 
compared to RFA, especially for patients with resectable tumors without extrahepatic 
disease (Wong et al., 2010). RFA investigators report a wide variability in the 5-yr survival 
rate (14% to 55%) and local tumor recurrence rate (3.6% to 60%). The reported mortality rate 
was low (0% to 2%), and the rate of major complications was commonly reported to be 6% 
to 9%. In another systematic review of the clinical benefit and role of radiofrequency 
ablation as treatment of colorectal liver metastases, the authors found that comparative 
studies indicated significantly improved overall survival after RFA versus chemotherapy 
alone, RFA plus chemotherapy versus RFA alone and up-front RFA versus RFA following 
second-line chemotherapy (Stang et al., 2009). The findings of these authors support the 
notion that RFA prolongs time without toxicity and survival as an adjunct to hepatectomy 
and/or chemotherapy in well-selected patients, but not as an alternative to resection. 
6. Outcomes and keys to success 
Treatment outcomes for patients with hepatic metastatic lesions from CRC have improved 
significantly over the last decade. This has been a result of a variety of factors, including 
improvements in surgical techniques and instrumentation, advances in chemotherapy, our 
understanding of tumor biology, but more importantly the use of multidisciplinary teams 
where the combined expertise of different specialties is used for the patient’s benefit. 
6.1 Outcome and recurrence after liver resection  
Five-year overall survival for patients with hepatic metastases from CRC treated with the 
combination of surgery and chemotherapy ranges anywhere from 45% to 65% for both open 
and laparoscopic liver resections (Castaing et al., 2009; Ito et al., 2008; Kazaryan et al., 2010). 
Recurrence can occur in as many as 60% of patients following liver resection of colorectal 
metastatic disease, with the most frequent site of recurrence being the liver; in 
approximately 20% of these patients the liver may be the only site of recurrence and as a 
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result these patients may be suitable for re-resection (Wong et al., 2010). The vast majorities 
of these recurrences occur in the first two years and for that reason frequent surveillance 
with CT is critical for early detection. This becomes even more important if we consider that 
the reported morbidity and mortality rates, as well as overall survival rates after re-
resection, despite the potential greater technical difficulty, are similar to those reported for 
the initial hepatectomy (Stang et al., 2009; Wong et al., 2010). In the current cost-conscious 
environment, the fact that intensive 3-monthly CT surveillance detects recurrence that is 
amenable to further resection in a considerable number of patients, leads to significantly 
better survival for these patients with a reasonable cost per life-year gained (Wanebo et al., 
1996). 
6.2 Use of multidisciplinary teams  
A key component for a successful outcome for patients with hepatic metastases from 
colorectal cancer is the close cooperation between the colorectal and the hepatobiliary team. 
Both of these should consist of specialist surgeons, in addition to an oncologist, 
gastroenterologist, diagnostic and interventional radiologist, histopathologist and clinical 
nurse specialist. The goal is to achieve a multidisciplinary input, as well as develop 
protocols that will be the cornerstone of developing a “best practices” approach. The 
improved outcomes that we are witnessing in the management of liver metastatic lesions 
from colorectal cancer are most likely the result of this concerted effort, as well as possibly a 
volume effect. 
7. Conclusion 
Patients with hepatic metastases from colorectal cancer represent a difficult challenge for the 
medical and surgical team caring for them, as we are dealing with an advanced stage of a 
disease.  However, the coordinated effort of the different specialties has made it possible to 
achieve 5-year survivals of 50% and in certain cases even talk about a cure. Central to this 
effort are the surgical advances and techniques that have allowed resection of these 
metastatic lesions in a safe and precise manner and have transformed the essential question 
from “what can be removed” to “what needs to be left behind”.  Patients and physicians 
undertaking this endeavour need to be prepared for a “marathon”, as when dealing with 
metastatic lesions one has to be prepared for recurrences and find ways to address them.  
However, with a combination of proper patient selection, choice of the appropriate strategy 
in terms of combining surgery with chemotherapy, and application of the right mixture of 
resection and ablation techniques, it is possible to achieve optimal oncologic results in this 
very challenging group of patients. 
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